The Food and Drug Administration has announced a pair of new additions to its team handling tobacco-related regulation and issues.
This morning Dr. Margaret Hamburg, M.D. appointed Robert Califf, M.D., a recognized global leader in cardiology, clinical research, and medical economics, as FDA Deputy Commissioner for Medical Products and Tobacco. Dr. Califf will provide executive leadership to the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health and the Center for Tobacco Products.
Among Dr. Califf’s responsibilities will be providing high-level advice and policy direction on the agency’s medical product and tobacco priorities.
Dr. Califf is currently serving as vice chancellor of clinical and translational research at Duke University and will join FDA in late February.
Additionally, the FDA announced that Ella Yeargin will be the Center for Tobacco Policy’s new Ombudsman beginning January 26, 2015. Yeargin began her federal career as a Presidential Management Fellow in 2011, working as a member of CTP’s FOIA team, then served in CTP’s Ombudsman’s office from 2012 to 2014, where she spent eight months as acting Ombudsman. Since November, she has served as a regulatory counsel in CTP’s Office of Compliance and Enforcement (OCE).
The CTP Ombudsman responds to inquiries and looks into complaints from the tobacco industry, law firms or consultants representing industry, advocacy groups, public and private research institutions, health care providers, and consumers; facilitates the resolution of disputes between CTP and outside parties; and provides general information on the regulatory process. While providing this assistance, the Ombudsman maintains independence, impartiality and neutrality.